8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
Iterum Therapeutics plc(ITRM)Earnings, Financials & Key Ratios
ITRM•NASDAQ
Price updated May 31, 2026
AboutIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$18M+59.7%
- Net Income-$25M+35.4%
- EPS (Diluted)-1.26+57.4%
ITRM Key Insights
Iterum Therapeutics plc (ITRM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 24.8%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 0 (bottom 0%)
- ✗Shares diluted 52.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ITRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ITRM Price & Volume
Iterum Therapeutics plc (ITRM) stock price & volume — 10-year historical chart
Loading chart...
ITRM Growth Metrics
Iterum Therapeutics plc (ITRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM62.5%
Return on Capital
10 Years-111.69%
5 Years-85.94%
3 Years-91.11%
Last Year-94.11%
ITRM Peer Comparison
Iterum Therapeutics plc (ITRM) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 SPRO | 132.02M | 2.28 | 15.20 | 24.27% | 27.82% | 35.58% | 0.05 | |
 VNDA | 342.83M | 5.80 | -1.55 | 8.72% | -109.99% | -61.41% | 0.04 | |
 CMPX | 279.34M | 2.02 | -4.81 | -100% | -39.75% | 0.05 | ||
 MTNB | 3.56M | 0.60 | -0.12 | -100% | -270.65% | 0.38 | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 TARS | 2.72B | 63.16 | -39.72 | 146.71% | -9.02% | -14.19% | 0.27 |
Compare ITRM vs Peers
Iterum Therapeutics plc (ITRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ITRM Income Statement
Iterum Therapeutics plc (ITRM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 508K | 869K | 37K | 0 | 0 | 0 | 0 | 0 | 390K |
Revenue Growth % | - | - | 71.06% | -95.74% | -100% | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 161K | 2.1M | 1.8M | 1.75M | 254K | 1.06M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 508K▲ 0% | 869K▲ 71.1% | 37K▼ 95.7% | -161K▼ 535.1% | -2.1M▼ 1206.8% | -1.8M▲ 14.4% | -1.75M▲ 2.8% | -254K▲ 85.5% | -668K▲ 0% |
Gross Margin % | - | 100% | 100% | 100% | - | - | - | - | - | -171.28% |
Gross Profit Growth % | - | - | 71.06% | -95.74% | -535.14% | -1206.83% | 14.45% | 2.78% | 85.49% | - |
Operating Expenses | 13.36M | 29.96M | 77.43M | 102.06M | 31.96M | 22.43M | 28.58M | 45.72M | 18.44M | 19.62M |
OpEx % of Revenue | - | 5898.23% | 8910.01% | 275832.43% | - | - | - | - | - | - |
Selling, General & Admin | 3.26M | 4.46M | 8.78M | 11.28M | 11.05M | 13.82M | 12.77M | 7.48M | 7.98M | 15.57M |
SG&A % of Revenue | - | 878.74% | 1010.47% | 30497.3% | - | - | - | - | - | - |
Research & Development | 10.1M | 25.5M | 68.65M | 90.77M | 20.91M | 8.61M | 15.82M | 38.24M | 10.46M | 3.8M |
R&D % of Revenue | - | 5019.49% | 7899.54% | 245335.14% | - | - | - | - | - | - |
Other Operating Expenses | 8K | 0 | 401K | 196K | 0 | 0 | 0 | 0 | 0 | 254K |
Operating Income | -13.36M▲ 0% | -29.45M▼ 120.5% | -76.56M▼ 159.9% | -102.02M▼ 33.3% | -32.13M▲ 68.5% | -24.54M▲ 23.6% | -30.38M▼ 23.8% | -47.47M▼ 56.2% | -18.7M▲ 60.6% | -20.29M▲ 0% |
Operating Margin % | - | -5798.23% | -8810.01% | -275732.43% | - | - | - | - | - | -5202.82% |
Operating Income Growth % | - | -120.49% | -159.92% | -33.26% | 68.51% | 23.62% | -23.83% | -56.23% | 60.61% | - |
EBITDA | 0 | -29.39M | -76.42M | -101.87M | -31.96M | -22.43M | -28.58M | -45.72M | -18.41M | -18.98M |
EBITDA Margin % | - | -5785.43% | -8794.36% | -275321.62% | - | - | - | - | - | -4865.38% |
EBITDA Growth % | - | - | -160.03% | -33.3% | 68.62% | 29.82% | -27.41% | -59.95% | 59.73% | 27% |
D&A (Non-Cash Add-back) | 13.36M | 65K | 136K | 152K | 161K | 2.1M | 1.8M | 1.75M | 284K | 1.32M |
EBIT | -13.35M | -29.45M | -76.16M | -101.83M | -36.17M | -85.31M | -41.77M | -36.33M | -22.01M | -24.39M |
Net Interest Income | 0 | 277K | -426K | -861K | -15.09M | -5.55M | -2.36M | 1.43M | 0 | -2.17M |
Interest Income | 0 | 277K | 0 | 0 | 12.3K | 4.53K | 2.36K | 1.43M | 0 | 133K |
Interest Expense | 0 | 0 | 426K | 861K | 15.1M | 5.55M | 2.36M | 0 | 0 | 2.3M |
Other Income/Expense | 8K | 493K | -25K | -665K | -19.14M | -66.32M | -13.75M | 9.71M | -5.84M | -6.39M |
Pretax Income | -13.35M▲ 0% | -28.96M▼ 116.9% | -76.58M▼ 164.4% | -102.69M▼ 34.1% | -51.26M▲ 50.1% | -90.86M▼ 77.2% | -44.13M▲ 51.4% | -37.76M▲ 14.4% | -24.53M▲ 35.0% | -26.68M▲ 0% |
Pretax Margin % | - | -5701.18% | -8812.89% | -277529.73% | - | - | - | - | - | -6842.31% |
Income Tax | 113K | 444K | 472K | 444K | 743K | 705K | 301K | 613K | 240K | 276K |
Effective Tax Rate % | -0.85% | -1.53% | -0.62% | -0.43% | -1.45% | -0.78% | -0.68% | -1.62% | -0.98% | -1.03% |
Net Income | -13.46M▲ 0% | -29.41M▼ 118.4% | -77.06M▼ 162.0% | -103.13M▼ 33.8% | -52.01M▲ 49.6% | -91.56M▼ 76.1% | -44.43M▲ 51.5% | -38.37M▲ 13.6% | -24.77M▲ 35.4% | -26.96M▲ 0% |
Net Margin % | - | -5788.58% | -8867.2% | -278729.73% | - | - | - | - | - | -6913.08% |
Net Income Growth % | - | -118.4% | -162.04% | -33.84% | 49.57% | -76.06% | 51.47% | 13.64% | 35.44% | 11.76% |
Net Income (Continuing) | -13.46M | -29.41M | -77.06M | -103.13M | -52.01M | -91.56M | -44.43M | -38.37M | -24.77M | -26.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -26.59▲ 0% | -58.08▼ 118.4% | -98.32▼ 69.3% | -7.10▲ 92.8% | -32.49▼ 357.6% | -8.41▲ 74.1% | -3.63▲ 56.8% | -2.96▲ 18.5% | -1.26▲ 57.4% | -0.59▲ 0% |
EPS Growth % | - | -118.43% | -69.28% | 92.78% | -357.61% | 74.12% | 56.84% | 18.46% | 57.43% | 62.5% |
EPS (Basic) | -26.59 | -58.08 | -98.32 | -7.10 | -32.49 | -8.41 | -3.63 | -2.96 | -1.26 | - |
Diluted Shares Outstanding | 13.96M | 549.15K | 631.57K | 1.05M | 24.01M | 10.89M | 12.24M | 12.96M | 19.7M | 45.8M |
Basic Shares Outstanding | 13.96M | 549.15K | 631.57K | 1.05M | 24.01M | 10.89M | 12.24M | 12.96M | 19.7M | 45.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ITRM Balance Sheet
Iterum Therapeutics plc (ITRM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.86M | 44.17M | 84.67M | 9.38M | 21.47M | 83.27M | 62.44M | 25.6M | 24.79M | 13.73M |
Cash & Short-Term Investments | 24.81M | 39.22M | 84.67M | 4.83M | 14.57M | 81.34M | 60.8M | 23.93M | 24.13M | 11M |
Cash Only | 24.81M | 8.48M | 44.55M | 4.83M | 14.57M | 27.45M | 21.09M | 6.07M | 24.13M | 11M |
Short-Term Investments | 0 | 30.73M | 40M | 0 | 0 | 53.9M | 39.71M | 17.86M | 0 | 0 |
Accounts Receivable | 245K | 509K | 721K | 1.11M | 865K | 1.21M | 513K | 233K | 66K | 546K |
Days Sales Outstanding | - | 365.72 | 302.84 | 10.96K | - | - | - | - | - | 166.36 |
Inventory | 0 | 0 | -7.87M | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 226.83 |
Other Current Assets | 0 | 180K | 959K | 1.14M | 5.24M | 37K | 35K | 0 | 65K | 0 |
Total Non-Current Assets | 1.05M | 2.58M | 13.2M | 16.37M | 11.32M | 8.24M | 4.39M | 663K | 19.81M | 18.78M |
Property, Plant & Equipment | 0 | 747K | 700K | 7.72M | 5.68M | 3.83M | 1.84M | 600K | 23K | 18K |
Fixed Asset Turnover | - | 0.68x | 1.24x | 0.00x | - | - | - | - | - | 21.97x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 3.44M | 1.72M | 0 | 19.75M | 18.71M |
Long-Term Investments | 0 | 0 | 959K | 60K | 248K | 64K | 34K | 0 | 0 | 63K |
Other Non-Current Assets | 1.05M | 1.84M | 11.54M | 8.6M | 5.39M | 912K | 797K | 63K | 39K | 19K |
Total Assets | 26.92M▲ 0% | 46.76M▲ 73.7% | 97.87M▲ 109.3% | 25.75M▼ 73.7% | 32.79M▲ 27.3% | 91.51M▲ 179.1% | 66.83M▼ 27.0% | 26.26M▼ 60.7% | 44.59M▲ 69.8% | 32.5M▲ 0% |
Asset Turnover | - | 0.01x | 0.01x | 0.00x | - | - | - | - | - | 0.01x |
Asset Growth % | - | 73.71% | 109.32% | -73.69% | 27.34% | 179.06% | -26.97% | -60.71% | 69.83% | 381.94% |
Total Current Liabilities | 4.22M | 7.13M | 12.22M | 36.99M | 41.7M | 12.94M | 9.06M | 13.52M | 17.61M | 6.43M |
Accounts Payable | 1.48M | 3.15M | 4.04M | 15.49M | 816K | 878K | 2.77M | 5M | 251K | 577K |
Days Payables Outstanding | - | - | - | - | 1.85K | 152.31 | 562.51 | 1.04K | 360.69 | 209.58 |
Short-Term Debt | 0 | 0 | 1.02M | 6.38M | 7.06M | 2.09M | 332K | 0 | 14.46M | 281K |
Deferred Revenue (Current) | 0 | 0 | 113K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.95M | 2.92M | 5.24M | 13.71M | 32.75M | 8.98M | 3.99M | 761K | 240K | 4.67M |
Current Ratio | 6.13x | 6.20x | 6.93x | 0.25x | 0.51x | 6.43x | 6.89x | 1.89x | 1.41x | 2.13x |
Quick Ratio | 6.13x | 6.20x | 7.57x | 0.25x | 0.51x | 6.43x | 6.89x | 1.89x | 1.41x | 1.96x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 183.61 |
Total Non-Current Liabilities | 30K | 137K | 26.25M | 15M | 41.65M | 28.33M | 29.77M | 19.14M | 31.07M | 33.45M |
Long-Term Debt | 0 | 0 | 13.08M | 7.63M | 35.85M | 24.9M | 28.47M | 18.96M | 31.07M | 33.45M |
Capital Lease Obligations | 0 | 0 | 0 | 6.75M | 5.17M | 3.44M | 1.3M | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30K | 137K | 951K | 630K | 630K | 0 | 0 | 188K | 0 | 0 |
Total Liabilities | 4.25M | 7.26M | 26.25M | 51.99M | 83.35M | 41.27M | 38.83M | 32.66M | 48.68M | 39.88M |
Total Debt | 0 | 0 | 13.08M | 20.75M | 48.08M | 30.43M | 30.1M | 18.96M | 45.53M | 33.73M |
Net Debt | -24.81M | -8.48M | -31.47M | 15.92M | 33.52M | 2.98M | 9.01M | 12.88M | 21.41M | 22.73M |
Debt / Equity | - | - | 0.18x | - | - | 0.61x | 1.08x | - | - | -4.57x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.78x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.20x |
Interest Coverage | - | - | -178.77x | -118.26x | -2.40x | -15.36x | -17.69x | - | - | -10.61x |
Total Equity | 22.67M▲ 0% | 39.49M▲ 74.2% | 71.62M▲ 81.3% | -26.24M▼ 136.6% | -50.56M▼ 92.7% | 50.23M▲ 199.4% | 28M▼ 44.3% | -6.4M▼ 122.9% | -4.08M▲ 36.3% | -7.38M▲ 0% |
Equity Growth % | - | 74.23% | 81.35% | -136.63% | -92.69% | 199.36% | -44.26% | -122.87% | 36.26% | 194.97% |
Book Value per Share | 1.62 | 71.92 | 113.40 | -24.99 | -2.11 | 4.61 | 2.29 | -0.49 | -0.21 | -0.16 |
Total Shareholders' Equity | 22.67M | 39.49M | 71.62M | -26.24M | -50.56M | 50.23M | 28M | -6.4M | -4.08M | -7.38M |
Common Stock | 4K | 4K | 144K | 149K | 494K | 1.83M | 126K | 135K | 315K | 490K |
Retained Earnings | -25.33M | -54.74M | -131.79M | -234.92M | -286.93M | -378.49M | -422.93M | -461.3M | -486.07M | -506.45M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -65K | -201K | 0 | 0 | 0 | -350K | 1K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ITRM Cash Flow Statement
Iterum Therapeutics plc (ITRM) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.3M | -30.6M | -75.89M | -81.92M | -54.53M | -15.84M | -18.47M | -39.33M | -26.77M | -19.91M |
Operating CF Margin % | - | -6024.41% | -8733.03% | -221410.81% | - | - | - | - | - | - |
Operating CF Growth % | - | -170.88% | -147.97% | -7.95% | 33.44% | 70.95% | -16.61% | -112.91% | 31.93% | -20.52% |
Net Income | -13.46M | -29.41M | -77.06M | -103.13M | -52.01M | -91.56M | -44.43M | -38.37M | -24.77M | -26.96M |
Depreciation & Amortization | 0 | 65K | 136K | 152K | 161K | 2.1M | 1.8M | 1.75M | 284K | 1.32M |
Stock-Based Compensation | 348K | 392K | 1.29M | 2.17M | 2.76M | 4.32M | 22.11M | 784K | 363K | 206K |
Deferred Taxes | 0 | 44K | -701K | 0 | 1.41M | 61.6M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -830K | -95K | 2.04M | 984K | 17.71M | 8.14M | -258K | -6.26M | 10.09M | 8.42M |
Working Capital Changes | 1.82M | -1.6M | -1.6M | 17.9M | -24.56M | -440K | 2.31M | 2.76M | -12.73M | -2.9M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.17M |
Change in Payables | 1.19M | 1.67M | 849K | 11.45M | -14.67M | 63K | 1.9M | 2.22M | -4.75M | -279.19K |
Cash from Investing | 0 | -31.59M | -8.66M | 40.1M | -11K | -54.59M | 13.96M | 23.34M | 18.21M | 1.09M |
Capital Expenditures | 0 | -812K | -90K | -24K | -11K | -61K | -62K | -13K | -2K | -14.57K |
CapEx % of Revenue | - | 159.84% | 10.36% | 64.86% | - | - | - | - | - | 3.73% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 54.53K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -30.77K | -8.57K | 0 | 0 | -54.53K | 0 | 0 | 0 | 0 |
Cash from Financing | 20.85M | 45.87M | 120.84M | 2.06M | 64.47M | 83.13M | -1.82M | 1.03M | 26.69M | 16.27M |
Debt Issued (Net) | 0 | 0 | 14.51M | -1.03M | -5.49M | -6.52M | -2.25M | 0 | 0 | -109.46K |
Equity Issued (Net) | 20.85M | 45.87M | 106.33M | 3.04M | 69.96M | 89.64M | 433K | 1.03M | 26.69M | 31.12M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 60K | 0 | 0 | 0 | 0 | 0 | -14.74M |
Net Change in Cash | 9.55M▲ 0% | -16.32M▼ 270.9% | 36.19M▲ 321.7% | -39.78M▼ 209.9% | 9.93M▲ 124.9% | 12.69M▲ 27.9% | -6.38M▼ 150.3% | -15.02M▼ 135.3% | 18.05M▲ 220.2% | -2.4M▲ 0% |
Free Cash Flow | -11.3M▲ 0% | -31.42M▼ 178.1% | -75.98M▼ 141.9% | -81.95M▼ 7.9% | -54.54M▲ 33.4% | -15.9M▲ 70.8% | -18.54M▼ 16.6% | -39.34M▼ 112.3% | -26.77M▲ 32.0% | -19.93M▲ 0% |
FCF Margin % | - | -6184.25% | -8743.38% | -221475.68% | - | - | - | - | - | -5110.05% |
FCF Growth % | - | -178.07% | -141.85% | -7.85% | 33.45% | 70.84% | -16.55% | -112.26% | 31.95% | 43.64% |
FCF per Share | -0.81 | -57.21 | -120.30 | -78.04 | -2.27 | -1.46 | -1.51 | -3.04 | -1.36 | -0.44 |
FCF Conversion (FCF/Net Income) | 0.84x | 1.04x | 0.98x | 0.79x | 1.05x | 0.17x | 0.42x | 1.02x | 1.08x | 0.74x |
Interest Paid | 0 | 0 | 809K | 1.4M | 996K | 416K | 22K | 0 | 0 | 0 |
Taxes Paid | 130K | 439K | 352K | 414K | 120K | 435K | 821K | 401K | 220K | 81K |
ITRM Key Ratios
Iterum Therapeutics plc (ITRM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -94.61% | -138.69% | -454.48% | - | -182.28% | -113.59% | -355.35% | - | 602.38% |
Return on Invested Capital (ROIC) | -153.05% | -161.38% | -512.94% | - | -101.76% | -50.51% | -163.72% | -117.78% | -93.44% |
Gross Margin | 100% | 100% | 100% | - | - | - | - | - | -171.28% |
Net Margin | -5788.58% | -8867.2% | -278729.73% | - | - | - | - | - | -6913.08% |
Debt / Equity | - | 0.18x | - | - | 0.61x | 1.08x | - | - | -4.57x |
Interest Coverage | - | -178.77x | -118.26x | -2.40x | -15.36x | -17.69x | - | - | -10.61x |
FCF Conversion | 1.04x | 0.98x | 0.79x | 1.05x | 0.17x | 0.42x | 1.02x | 1.08x | 0.74x |
Revenue Growth | - | 71.06% | -95.74% | -100% | - | - | - | - | - |
Related:ITRM Dividend History·ITRM Revenue History·ITRM Price History·ITRM P/E History·ITRM Financial Ratios·ITRM Institutional Holders
ITRM SEC Filings & Documents
Iterum Therapeutics plc (ITRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
ITRM Frequently Asked Questions
Iterum Therapeutics plc (ITRM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Iterum Therapeutics plc (ITRM) reported $0.4M in revenue for fiscal year 2024.
Iterum Therapeutics plc (ITRM) grew revenue by 0.0% over the past year. Growth has been modest.
Iterum Therapeutics plc (ITRM) reported a net loss of $27.0M for fiscal year 2024.
Dividend & Returns
Iterum Therapeutics plc (ITRM) had negative free cash flow of $19.9M in fiscal year 2024, likely due to heavy capital investments.